Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA class I heavy chains are the α chains of human leukocyte antigen (HLA) class I molecules, which are essential components of the immune system. These molecules present intracellularly derived peptide antigens to CD8+ cytotoxic T lymphocytes, enabling immune surveillance and response against infected or malignant cells. The HLA class I molecule is a heterodimer composed of a polymorphic heavy chain (α chain), and a non-polymorphic light chain called β2-microglobulin (β2M). The α chain (~44–47 kDa) consists of three extracellular domains: α1, α2, and α3, a transmembrane region, and a short cytoplasmic tail. The α1 and α2 domains form the peptide-binding groove. The heavy chain is highly polymorphic—this diversity underlies individual differences in immune responses as different alleles present different sets of peptides.
Modulation of T cell activation through altered antigen presentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA Class I Heavy Chain (HLA Class I).